Device brand name · Ureteral stent
Bard InLay Optima Ureteral Stent: medical device reports filed with FDA
394 reports name it, 2017–2026. Manufacturer given most often on reports: C R Bard Covington -1018233. Product code FAD.
- 394
- device reports naming the brand
- 0% of all MAUDE reports · about 43 a year
- 44
- reports, 12 months to August 2026
- 86 in the 12 months before
- 79.2%
- classified as malfunction
- 70.6% across the product code
- 0%
- classified as death, as reported
- 0 reports · not verified by FDA
FDA's MAUDE database holds 394 reports that name the brand "Bard InLay Optima Ureteral Stent" (ureteral stent), received between May 2017 and August 2026; the manufacturer given most often on reports is C R Bard Covington -1018233. Spellings of one product vary from report to report.
44 reports arrived in the 12 months to August 2026, down 49% from 86 in the 12 months before. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases. The event types recorded are malfunction (79.2%) and injury (20.8%); across all stent, ureteral reports (product code FAD) death is recorded in 0.2% and malfunction in 70.6%. Event type is the reporter's classification of the report, not a verified outcome.
The device problems coded most often are material fragmentation (44.4%), calcified (12.7%) and material twisted/bent (4.8%). The patient problems coded most often are appropriate clinical signs, symptoms and conditions term/code not available, foreign body in patient and pain. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Reports by month, five years
Reports by the month FDA received them. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases.
By year received
Event type and report source
Event type, as classified on the report
Who filed the report
Grey bar: all 5,909 reports carrying product code FAD. Event type is the filer's classification and is not verified by FDA.
Device problems coded
| Device problem (FDA code) | Reports | Share | Share across product code |
|---|---|---|---|
| Material fragmentation | 175 | 44.4% | 10.1% |
| Calcified | 50 | 12.7% | 8% |
| Material twisted/bent | 19 | 4.8% | 1.1% |
| Patient device interaction problem | 17 | 4.3% | 2.2% |
| Biocompatibility | 10 | 2.5% | 1.7% |
| Accessory incompatible | 9 | 2.3% | 0.7% |
| Tear, rip or hole in device packaging | 9 | 2.3% | 0.6% |
| Difficult to insertthe device was hard to insert | 8 | 2% | 0.9% |
| Fracturea broken bone | 8 | 2% | 2.1% |
| Migrationthe device moved from where it was placed | 8 | 2% | 2.9% |
| Material too rigid or stiff | 7 | 1.8% | 0.6% |
| Deformation due to compressive stress | 6 | 1.5% | 2.8% |
| Material split, cut or torn | 6 | 1.5% | 3.9% |
| Component missing | 5 | 1.3% | 0.7% |
| Device dislodged or dislocated | 5 | 1.3% | 0.8% |
| Device handling problem | 5 | 1.3% | 0.2% |
| Partial blockage | 5 | 1.3% | 0.7% |
| Difficult to removethe device was hard to remove | 4 | 1% | 6.8% |
| Incomplete or missing packaging | 4 | 1% | 0.1% |
| Device contamination with chemical or other material | 3 | 0.8% | 0.6% |
FDA's device problem codes as entered on the report; one report can carry several. Generic codes such as "no apparent adverse event" are left out.
Patient problems coded
| Patient problem (FDA code) | Reports | Share |
|---|---|---|
| Appropriate clinical signs, symptoms and conditions term/code not available | 52 | 13.2% |
| Foreign body in patientpart of a device left in the patient | 14 | 3.6% |
| Painpain, site not specified | 13 | 3.3% |
| Calcium deposits/calcification | 7 | 1.8% |
| Hematuria | 7 | 1.8% |
| No patient involvement | 7 | 1.8% |
| Swelling/ edema | 4 | 1% |
| Exposure to body fluids | 3 | 0.8% |
| Hemorrhage/blood loss/bleeding | 3 | 0.8% |
| Fever | 2 | 0.5% |
| Irritabilityirritability | 2 | 0.5% |
| Laceration(s) | 2 | 0.5% |
| Abrasion | 1 | 0.3% |
| Discomfortdiscomfort | 1 | 0.3% |
| Hypersensitivity/allergic reaction | 1 | 0.3% |
Patient problem codes are present mainly in reports filed since 2019 and are often blank.
In context
| Measure | Bard InLay Optima Ureteral Stent | Product code FAD | All MAUDE reports |
|---|---|---|---|
| Reports | 394 | 5,909 | 26,136,888 |
| Share of that pool | — | 6.7% | 0% |
| Classified as death, per 1,000 reports | 0 | 2 | 9 |
| Classified as injury | 20.8% | 28.5% | 36.2% |
| Classified as malfunction | 79.2% | 70.6% | 62.3% |
| Filed by the manufacturer | 99.7% | 94.5% | 94.9% |
Shares are of reports, not of devices in use. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Other brands with product code FAD
| Brand | Reports | Latest 12 months | Classified as death |
|---|---|---|---|
| Polaris? Ultra | 478 | 49 | 0% |
| Bard InLay Ureteral Stent with HydroGlide Guidewire | 342 | 17 | 0% |
| Percuflex Plus | 458 | 50 | 0.4% |
| Resonance Stent Set | 256 | 16 | 1.2% |
| Bard InLay Ureteral Stent | 232 | 25 | 0% |
| Filiform Double Pigtail Ureteral Stent Set | 227 | 38 | 0.4% |
| Bard InLay Optima Ureteral Stent with HydroGlide Guidewire | 220 | 14 | 0% |
| Universa Soft Ureteral Stent Set | 205 | 14 | 0% |
| Universa Firm Ureteral Stent Set | 203 | 12 | 0% |
| Contour | 2,235 | 38 | 0% |
| Polaris? Loop | 154 | 25 | 0.6% |
| Flexima? | 257 | 10 | 0.4% |
| Boston Scientific | 580 | 5 | 3.3% |
| Cotton-Leung Biliary Stent | 271 | 20 | 1.1% |
| Cook | 271 | 6 | 2.2% |
Ordered by report count for navigation only. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA also states that "common products may have a higher number of adverse events due to the higher total number of people using the product."
Questions about Bard InLay Optima Ureteral Stent reports
How many FDA reports name Bard InLay Optima Ureteral Stent?
394 medical device reports in the openFDA MAUDE release of 28 Sep 2026, covering reports received through August 2026; 44 in the latest 12 months.
What kinds of events are reported?
malfunction (79.2%) and injury (20.8%). "Event type" is how the report was classified when filed: death, injury, malfunction or other.
What device problems are coded?
material fragmentation (44.4%), calcified (12.7%), material twisted/bent (4.8%), patient device interaction problem (4.3%) and biocompatibility (2.5%). These are FDA's device problem codes as entered on the report.
Who files these reports?
manufacturer reports (99.7%). Manufacturers and user facilities are required to report; voluntary reports come from health professionals and the public.
Do these reports show that Bard InLay Optima Ureteral Stent was at fault?
No. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA adds that "a causal relationship cannot be established between product and reactions listed in a report."
How do I report a problem with a medical device?
Through FDA MedWatch (Form FDA 3500 for health professionals and consumers), or to the manufacturer. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Device Adverse Event (MAUDE) bulk export released 28 Sep 2026, which holds reports FDA received through 31 Aug 2026. Brand, generic and manufacturer names are as written on the reports; product code names come from FDA's device classification. A report counts here when any device it lists carries this brand name after punctuation and capitalisation are normalised. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.